Course Director

Paul Cornes, BA, BM BCH, MA, MRCP, FRCR
Paul Cornes, BA, BM BCH, MA, MRCP, FRCR

Comparative Outcomes Group
Bristol, United Kingdom


Arnold G. Vulto
Arnold G. Vulto, PharmD, PhD, FCP

Erasmus University Medical Center
Rotterdam, The Netherlands

Prof. Wojciech Jurczak
Prof. Wojciech Jurczak, MD, PhD

Jagiellonian University
Krakow, Poland

Accredited by

Oakstone Publishing, LLC

Activity Details

Credit Types:CME
Credit Amount:1.5 Credits
Release Date:2017-Jul-31
Expiration Date:2018-Jul-30
Estimated Time for Completion:90 minutes
Registration Required:No
Cost:Free of charge

Funding Disclosure

This educational activity is supported by Sandoz.

Activity Description and Educational Objectives

In this activity, experts in haematologic malignancies discuss the role of biosimilars in improving sustainability of care in the treatment of these diseases.

Upon completion of this activity, participants should be better able to:
  • Recognise the similarities and differences between biosimilars and originators
  • Review the role of biosimilars in sustainability of treatment for haematologic malignancies
  • Evaluate the data on monoclonal antibodies for the treatment of haematologic malignancies and the role of biosimilar monoclonal antibodies to address some lingering gaps in care

Target Audience

This activity has been designed to meet the educational needs of haematologist-oncologists, haematologists, and pharmacists, as well as other clinicians involved in the management of haematologic malignancies.

Faculty Disclosure Statement / Conflict of Interest Policy

Oakstone Publishing, LLC has assessed conflict of interest with its faculty, authors, editors, and any individuals who were in a position to control the content of this CME activity. Any identified relevant conflicts of interest were resolved for fair balance and scientific objectivity of studies utilized in this activity. Oakstone Publishing’s planners, medical reviewers, and editorial staff disclose no relevant financial relationships with commercial interests.

Course Director and Moderator

Paul Cornes, BA, BM BCH, MA, MRCP, FRCR
Oncologist, Comparative Outcomes Group
Bristol, United Kingdom

Paul Cornes, BA, BM BCH, MA, MRCP, FRCR, has a financial interest/relationship or affiliation in the form of:
Honoraria from Accord Healthcare; Amgen Inc; Bernstein & Co.; Eli Lilly and Company; F. Hoffmann-La Roche Ltd; Generic and Biosimilar Medicines Association (Australia); Hospira, Inc.; Janssen Pharmaceutical; Merck Serono Ltd; Napp Pharmaceutical Group Ltd; PhAMA (Pharmaceutical Association of Malaysia); Pfizer Ltd; Sandoz Ltd; Synsana EEIG; and Teva Pharmaceutical Industries Ltd.
Advisory Board for Hospira, Inc.; Pfizer Ltd; and Sandoz Ltd.


Arnold G. Vulto, PharmD, PhD, FCP
Professor of Hospital Pharmacy, Hospital Pharmacist and Pharmacologist,
Erasmus University Medical Center
Rotterdam, The Netherlands

Arnold G. Vulto, PharmD, PhD, FCP, has a financial interest/relationship or affiliation in the form of:
Consultant for AbbVie; Biogen Idec Ltd; Hospira, Inc.; Pfizer Inc; and Sandoz Ltd.
Speakers Bureau participant with Amgen Inc; Biogen Idec Ltd; F. Hoffmann-La Roche Ltd; Febelgen; Medicines for Europe AISBL; and Sandoz Ltd.
Advisory Board for Amgen Inc; Biogen Idec Ltd; Boehringer-Ingelheim; and Hexal AG.

Prof. Wojciech Jurczak, MD, PhD
Chair of Haematology, Jagiellonian University
Krakow, Poland

Prof. Wojciech Jurczak, MD, PhD, has a financial interest/relationship or affiliation in the form of:
Consultant for MorphoSys AG; Novartis AG; and Sandoz International GmbH.
Grant/Research Support from AbbVie; Centurion Pharma Ilac; Gilead Sciences, Inc; Janssen Biotech, Inc.; Novartis AG; Rode Pharma S.R.L.; Sandoz International GmbH; and Takeda Pharmaceutical Company Limited.

PeerVoice Medical Director

Sonia Schursky has no financial interests/relationships or affiliations in relation to this activity.

Disclosure of Unlabelled Use

The faculty of this educational activity may include discussions of products or devices that are not currently labelled for use in certain jurisdictions. Faculty members have been advised to disclose to the audience any reference to an unlabelled or investigational use.

No endorsement of unapproved products or uses is made or implied by coverage of these products or uses in our materials. No responsibility is taken for errors or omissions in our materials.

Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.


his activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Oakstone Publishing, LLC and PeerVoice. Oakstone Publishing, LLC is accredited by the ACCME to provide continuing medical education for physicians.

Oakstone Publishing, LLC designates this enduring material for a maximum of 1.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

The European Union of Medical Specialists (UEMS)-European Accreditation Council for Continuing Medical Education (EACCME) has an agreement of mutual recognition of continuing medical education (CME) credit with the American Medical Association (AMA). European physicians interested in converting AMA PRA Category 1 Credit™ into European CME credit (ECMEC) should contact the UEMS (

This CME activity is jointly provided by Oakstone Publishing, LLC and PeerVoice.

Requirements for Successful Completion

To receive credit, participants must complete the activity, the post-test, and the evaluation form prior to the expiration date noted below. There are no pre-requisites and there is no fee to participate in this activity or to receive credit. Statements of Credit are awarded upon successful completion of the post-test and evaluation form. Consult your professional licensing board for information about your eligibility to claim credit for participation in this educational activity. A minimum performance level of 70% is needed.

Media: Enduring Material
Release and Expiration Dates: July 31, 2017 - July 30, 2018
Time to Complete: 90 minutes


The participants of this educational activity have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patients' conditions and possible contraindications on dangers in use, review of any applicable manufacturer's product information, and comparison with recommendations of other authorities.

The materials presented here are used with the permission of the authors and/or other sources. These materials do not necessarily reflect the views of PeerVoice or any of its supporters.

For technical assistance, please contact us.

Suggest a CME Activity

Please provide below the URL and description of an activity you would like to add to OpenCME. You are welcome to add activities as often as you like. To prevent spam or other abuse, activities are reviewed by our editorial team before appearing on OpenCME.

OpenCME for Publishers

Please use the form below if you would like to offer your website visitors high-quality CME content by adding the OpenCME Widget to one or more of your pages.

Send Email to a Colleague

To share this activity with one or more colleagues, enter their e-mail addresses below. To include a personal message, simply overwrite the suggested text below.

(So your recipient knows it's from you.)
Enter multiple recipients separated by a space.
Optionally, replace/modify in the box above the message that will be sent to your colleague(s) with a link to download this app.